Belite Bio Inc ADR (BLTE) — Technical state
As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Signal: Mixed moving-average stack — Trades -2.7% vs the 50-day and -2.3% vs the 200-day average, 21.7% below the 52-week high and +53.5% off the 52-week low; a golden cross printed 47 sessions ago. Computed from daily closes. (as of 2026-11-10)
- Trend: Belite Bio Inc ADR trades 2.7% below its 50-day and 2.3% below its 200-day moving average. (as of 2026-11-10)
Belite Bio is a clinical-stage biopharmaceutical company that develops treatments for diseases with few existing options. Its main candidate, an orally administered drug called Tinlarebant, is in a phase 3 trial meant to protect retinal tissue in patients with Stargardt disease type 1 and geographic atrophy.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the BLTE overview. Research diary readings, not advice.
Trades -2.7% vs the 50-day and -2.3% vs the 200-day average, 21.7% below the 52-week high and +53.5% off the 52-week low; a golden cross printed 47 sessions ago. Computed from daily closes.
The moving-average stack
- vs 20-day+3.8%
- vs 50-day-2.7%
- vs 200-day-2.3%
- 52-week band21.7% off the high · +53.5% off the low
- Streak1 consecutive down session
- CrossoverGolden cross 47 sessions ago
- 50-day crossprice crossed down through the 50-day 28 sessions ago
- Stochastic%K 77.6 · %D 59.1
Continue: the BLTE chart & overview · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-10
Quick answers
What is the current Closelooknet signal on BLTE?
Mixed moving-average stack — Trades -2.7% vs the 50-day and -2.3% vs the 200-day average, 21.7% below the 52-week high and +53.5% off the 52-week low; a golden cross printed 47 sessions ago. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is BLTE above its 50-day and 200-day moving averages?
As of 2026-11-10, Belite Bio Inc ADR trades -2.7% below its 50-day and -2.3% below its 200-day average, with the 20-day +3.8% away.
How far is BLTE from its 52-week high?
21.7% below the 52-week high and 53.5% above the 52-week low, as of 2026-11-10.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- REPL Replimune Group Incindustry
- KOD Kodiak Sciences Incindustry
- XNCR Xencor Incindustry
- VCEL Vericel Corp Ordindustry
- VRDN Viridian Therapeutics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- MRNA Moderna Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- ORKA Oruka Therapeutics, Inc.industry
- ADMA ADMA Biologics Incindustry
- PHARM.AS Pharming Group NVindustry
- MEDCL.PA Medincell SAindustry
- DNA Ginkgo Bioworks Holdingsindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry